<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03749551</url>
  </required_header>
  <id_info>
    <org_study_id>TrueTypeCKD 4/17</org_study_id>
    <nct_id>NCT03749551</nct_id>
  </id_info>
  <brief_title>Towards Understanding the Phenotype of Cardiovascular Disease in CKD - TRUE-Type-CKD Study</brief_title>
  <acronym>TRUE-TypeCKD</acronym>
  <official_title>TowaRds Understanding the phEnoTYPEs of Cardiovascular Dysfunction in Patients With Chronic Kidney Disease and HaemoDialysis Using Cardiovascular Magnetic Resonance Imaging - TRUE-Type-CKD Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kerckhoff Klinik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Premature cardiovascular disease (CVD) is the leading cause of death in patients with kidney&#xD;
      disease (CKD). Excessive cardiac mortality is thought to be secondary to non-atherosclerotic&#xD;
      processes, with left ventricular (LV) hypertrophy (LVH) and remodelling being the predominant&#xD;
      phenotypical features. Along with other risk factors, subclinical ischaemia and haemodynamic&#xD;
      perturbations associated with haemodialysis (HD) are thought to contribute to the ultimate&#xD;
      development of LV systolic and diastolic dysfunction. The development of these adverse&#xD;
      features reflects a specific cardiomyopathy due to CKD and subsequently, to uraemia. Patients&#xD;
      receiving hemodialysis (HD) have a higher incidence rate of heart failure (predominantly with&#xD;
      preserved ejection fraction), with phenotypically eccentric hypertrophic remodelling,&#xD;
      systolic and diastolic dysfunction as well as high rate of interstitial myocardial fibrosis.&#xD;
      Detection and ultimately reversal of the development of this CKD-related cardiomyopathy are&#xD;
      important goals for improving the CVD, morbidity and mortality of CKD patients.The objectives&#xD;
      of this study are, firstly, to investigate the complex myocardial phenotype in patients with&#xD;
      various stages of CKD, secondly, to relate the CMR-measures to outcome, and thirdly, to be&#xD;
      able to estimate the effects of chronic uremia/hypervolemia. Deciphering the predominant&#xD;
      driver of remodelling on an individual level may help to personalise anti-remodelling&#xD;
      strategies. Native T1 and T2 mapping imaging provide non-invasive imaging tools to detect&#xD;
      myocardial fibrosis and oedema, respectively. Prognostic associations of these measures may&#xD;
      clarify the relative prevalence of adverse phenotype and their relative contribution to&#xD;
      adverse events and poor outcome. The role of chronic water retention and uraemia may be&#xD;
      associated with interstitial myocardial oedema promoting further the remodelling process.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Actual">June 14, 2021</completion_date>
  <primary_completion_date type="Actual">June 14, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>survival</measure>
    <time_frame>1 year</time_frame>
    <description>number of deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>survival</measure>
    <time_frame>5 year</time_frame>
    <description>number of deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of death due to cardiovascular causes</measure>
    <time_frame>1 year</time_frame>
    <description>number of participants died due to death due to myocardial infarction, sudden cardiac death, heart failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of death due to cardiovascular causes</measure>
    <time_frame>5 year</time_frame>
    <description>number of participants died due to death due to myocardial infarction, sudden cardiac death, heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of heart failure events</measure>
    <time_frame>1 year</time_frame>
    <description>number of participants with heart failure death and hospitalisation due to heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of heart failure events</measure>
    <time_frame>5 year</time_frame>
    <description>number of participants with heart failure death and hospitalisation due to heart failure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in native T1 and T2 (in msec) pre and post haemodialysis</measure>
    <time_frame>24 hour</time_frame>
    <description>measurement of change in magnetisation relaxation (in msec)</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">276</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiomyopathies</condition>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Hypertrophy, Left Ventricular</condition>
  <arm_group>
    <arm_group_label>Participants</arm_group_label>
    <description>diagnostic test - patients serving as their own controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>cardiac magnetic resonance (CMR) post haemodialysis</intervention_name>
    <description>patients will undergo a second CMR scan immediately after receiving haemodialysis (native CMR study)</description>
    <arm_group_label>Participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with established diagnosis of chronic kidney disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults &gt;18 years of age&#xD;
&#xD;
          2. Able to provide informed consent&#xD;
&#xD;
          3. Chronic kidney disease stages G3-5 (eGFR&lt;59 ml/min/1.73m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Absence of absolute clinical indication for MRI studies (MR unsafe or incompatible&#xD;
             devices, aneurysm clips, cochlear implants, loose metal foreign objects)&#xD;
&#xD;
          2. Absolute contraindications to gadolinium contrast agent (previous allergic reaction or&#xD;
             pregnancy),&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>Frankfurt am Main</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 17, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2018</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Valentina Puentmann</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

